Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | PDE2A | O00408 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4615254 | 1.00 | HSD17B10 (0.54) | HSD17B10GLAHSD11B1ALDH1A1MEN1 | |
| SCHEMBL3578457 | 0.88 | GLA (0.70) | HSD17B10GLAHSD11B1ALDH1A1MEN1 | |
| SCHEMBL3578454 | 0.88 | GLA (0.70) | HSD17B10GLAHSD11B1ALDH1A1MEN1 | |
| SCHEMBL1969349 | 0.86 | GLA (0.57) | HSD17B10GLAHSD11B1ALDH1A1MEN1 | |
| SCHEMBL4615244 | 0.86 | GLA (0.57) | HSD17B10GLAHSD11B1ALDH1A1MEN1 | |
| SCHEMBL5031105 | 0.84 | HSD11B1 (0.55) | HSD17B10GLAHSD11B1ALDH1A1MEN1 | |
| SCHEMBL5033309 | 0.81 | GLA (0.49) | HSD17B10GLAALDH1A1MEN1KMT2A | |
| SCHEMBL1970300 | 0.81 | GLA (0.49) | HSD17B10GLAALDH1A1MEN1KMT2A | |
| SCHEMBL4227278 | 0.79 | HSD11B1 (0.50) | HSD17B10GLAHSD11B1ALDH1A1MEN1 | |
| SCHEMBL3390856 | 0.78 | KMT2A (0.55) | HSD17B10HSD11B1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM3, GRM2 | HSD17B10 3397/4885GLA 4677/4885HSD11B1 3080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.